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Background
The role of pre-transplant salvage chemotherapy has been controversial in relapsed acute 
leukemia. 
Methods
We investigated post-transplant outcomes in 65 patients with acute leukemia treated with 
allogeneic hematopoietic cell transplantation (HCT) during first relapse or second 
remission. 
Results
The 5-year cumulative incidence of relapse (CIR) was 52.3%. Multivariate analysis for CIR 
revealed that patients with unfavorable cytogenetics and those not in remission at the 
time of HCT had a significantly high CIR (P=0.031 and P=0.031, respectively). Allogeneic 
HCT was performed in 14 patients after first relapse without salvage chemotherapy (“un-
treated relapse” group), 15 patients failed chemotherapy for reinduction of remission be-
fore HCT (“refractory relapse” group), and 36 patients attained second remission with 
salvage chemotherapy before HCT (“second remission” group). The 5-year CIR for pa-
tients in the untreated relapse group (57.1%) was higher than that for those in the second 
remission group (42.3%), but it was lower than that for patients in the refractory relapse 
group (66.7%). Among patients who underwent allogeneic HCT in relapse, those with 
bone marrow (BM) blasts ≤30% had a lower 5-year CIR than those in florid relapse (BM 
blasts ＞30%) (57.7% vs. 70.6%). 
Conclusion
Our results do not support the role of salvage chemotherapy aimed at re-induction of 
remission before allogeneic HCT in patients with acute leukemia after first relapse. 
Patients with early relapse do not appear to benefit from salvage chemotherapy before 
HCT.
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INTRODUCTION
Treatment outcome in young acute leukemia patients has 
improved over the past 2 decades, with complete remission 
(CR) rates ranging from 60-80% [1, 2]. However, 50-70% 
of patients in the first CR eventually relapse, and these pa-
tients have poor prognosis. Although a number of chemo-
therapeutic agents alone and in combination with other drugs 
have been tested, the CR rate in relapsed patients is very 
low and any remission with chemotherapy alone is usually 
short-lived [3-7]. For these patients, allogeneic hemato-
poietic cell transplantation (HCT) may offer the only chance 
for cure. The probability of disease-free survival (DFS) 5 
years after HCT is about 20% to 30% [8-11]. The timing 
of allogeneic HCT in patients who relapse after the first 
CR may be important. Moreover, it is difficult to determine 
whether reinduction therapy should be attempted or HCT Korean J Hematol 2010;45:95-101.
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Table 1. Patient and transplantation characteristics.
Characteristic
Sex, M/F  34 (52.3%)/31 (47.7%)
Age, years, median (range) 34 (16-61)
Diagnosis, AML/ALL/BAL 43 (66.2%)/20 (30.8%)/2 (3.1%)
Time from diagnosis to HCT, days, median (range) 400 (98-1,974)
Duration of first CR, days, median (range) 275 (28-1,405)
Disease status at transplantation
First relapse, untreated
First relapse, refractory to salvage chemotherapy
Second CR
14 (21.5%)
15 (23.1%)
36 (55.4%)
Cytogenetic findings at diagnosis
Normal 
t(15;17)/t(8;21)/inv(16)
t(9;22)/Complex
Other/Unknown 
14 (21.5%)
3 (4.6%)/10 (15.4%)/1 (1.5%)
7 (10.8%)/4 (6.2%)
16 (24.6%)/10 (15.4%)
Bone marrow blasts, %
＜5%/5–30%/＞30% 36 (58.1%)/9 (14.5%)/17 (27.4%)
Presence of circulating blasts at transplantation  20 (30.8%)
Extramedullary involvement at transplantation 6 (9.2%)
Preparative regimen
BuCy/TBI containing/RIC 42 (64.6%)/13 (20.0%)/10 (15.4%)
GVHD prophylaxis
CSA-MTX/CSA/CSA+CS
Tacrolimus-MTX/MTX+CS/CS
39 (60.0%)/17 (26.2%)/4 (6.2%)
3 (4.6%)/1 (1.5%)/1 (1.5%)
Type of donor
Sibling/Unrelated
Parent or offspring/Cord blood
40 (61.5%)/21 (32.3%)
2 (3.1%)/2 (3.1%)
HLA match (ABDR), donor-recipient, match/mismatch 56 (86.2%)/6 (13.8%)
Tissue for graft, BM/PB/CB 48 (73.8%)/15 (23.1%)/2 (3.1%)
T-cell depletion of donor graft 7 (10.8%)
Sex pair, donor-recipient, F to M/other 14 (22.2%)/49 (77.8%)
Donor age, years, median (range) 32 (18-65)
Abbreviations: M, male; F, female; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BAL, biphenotypic acute leukemia; HCT,
hematopoietic cell transplantation; CR, complete remission; BuCy, busulfan-cyclophosphamide; TBI, total body irradiation; RIC, 
reduced-intensity conditioning; CSA, cyclosporine; MTX, methotrexate; CS, corticosteroid; BM, bone marrow; PB, peripheral blood; CB, cord
blood.
should be directly performed in relapsed patients with histo-
compatible donors. Several studies have reported contra-
dictory results, with some favoring HCT without reinduction 
therapy [8, 10, 12, 13], while others emphasized the im-
portance of CR before HCT [11, 14, 15].
In this study, we retrospectively investigated the clinical 
outcomes of acute leukemia patients who underwent alloge-
neic HCT after first relapse and analyzed the role of salvage 
chemotherapy aimed at the reinduction of remission before 
allogeneic HCT.
MATERIALS AND METHODS
1. Patients and transplantation procedure
We retrospectively reviewed the records of 65 consecutive 
adult patients who had received allogeneic HCT for acute 
leukemia at first relapse or second CR at 3 institutes in 
Seoul, Korea, between January 1995 and September 2004 
(Table 1). Acute myeloid leukemia (AML) was the underlying 
disease in 43 patients (66.2%), acute lymphoblastic leukemia 
(ALL) in 20 (30.8%), and biphenotypic acute leukemia in 
2 (3.1%). All patients had previously achieved CR and had 
relapsed after a median CR duration of 275 days (range, 
28-1,405 days). The attending physician at each institute 
decided whether to attempt reinduction therapy or to pro-
ceed directly to HCT. Fourteen patients (21.5%) underwent 
allogeneic HCT after first relapse without salvage chemo-
therapy aimed at the reinduction of remission (“untreated 
relapse” group), 15 patients (23.1%) failed to achieve CR 
with intensive chemotherapy for re-induction of remission 
before HCT (“refractory relapse” group), and 36 patients 
(55.4%) attained second CR with salvage chemotherapy be-
fore HCT (“second remission” group). Salvage chemotherapy 
regimens varied: cytarabine plus anthracycline-based regi-
mens were administered in most patients with AML and 
vincristine, prednisolone plus daunorubicin-based regimens 
were administered in most patients with ALL. Cytogenetic 
analyses were successfully performed in 55 patients at 
diagnosis. Of the 29 patients who were not in remission Korean J Hematol 2010;45:95-101.
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Fig. 1. Overall survival and event-free survival curves. Fig. 2. Cumulative incidences of relapse and non-relapse mortality.
before HCT, 9 had ≤30% bone marrow (BM) blasts and 
17 had ＞30% blasts; the blast percentage for the other 3 
patients was not available.
Preparative regimens for allogeneic HCT were dependent 
on the treatment strategy at each institute and the attending 
physician’s discretion (Table 1). Regimens included cyclo-
phosphamide (120 mg/kg) plus oral busulfan (16 mg/kg) or 
intravenous busulfan (12.8 mg/kg), 12.0 Gy of total body 
irradiation (TBI) plus cyclophosphamide (120 mg/kg), 10.0- 
2.0 Gy of TBI plus combinations with other chemothera-
peutic agents, and various reduced-intensity conditioning 
regimens, which fulfilled one of the following criteria: (1) 
500 cGy or less of TBI, (2) 9 mg/kg or less of total busulfan 
dose, (3) 140 mg/m
2  or less of total melphalan dose, and 
(4) regimen included the purine analog fludarabine [16]. 
Fifty-six donors were HLA-ABDR-matched and 6 donors 
were mismatched with their respective recipients.
2. Statistical analysis
The probabilities of overall survival (OS) and event-free 
survival (EFS) were calculated by the Kaplan-Meier method 
[17] and compared by a log-rank test [18]. For the calculation 
of EFS, only surviving patients without relapse were censored 
at the last follow-up date. The effects of variables that 
changed with time after HCT, such as graft-versus-host dis-
ease (GVHD), on survival were analyzed in a time-dependent 
fashion using Cox regression models [19]. 
For the analysis of the cumulative incidence of relapse 
(CIR), patients who were alive without relapse were cen-
sored, whereas those who died without relapse were counted 
as competing cause of failure [20]. For the analysis of the 
cumulative incidence of non-relapse mortality (NRM), pa-
tients who relapsed were counted as competing cause of 
failure. The cumulative incidence was calculated and com-
pared by Gray’s method [21].
Statistically or marginally significant prognostic factors 
identified by univariate analysis were entered into an appro-
priate multivariate model (Cox proportional hazards re-
gression model for OS and EFS [22] and Gray’s method 
for CIR and NRM).
RESULTS
1. Post-transplant outcomes
Acute graft-versus-host disease (GVHD) occurred in 17 
(26.6%) of 64 evaluable patients on median day 26 and chron-
ic GVHD occurred in 15 (27.8%) of 54 evaluable patients 
on median day 150.
A median follow-up for 673 days (range, 151-3,010 days) 
among surviving patients indicated that 34 had relapsed and 
49 had died. We observed 56 events (deaths or relapses). 
Of the 49 deaths, 22 were not related to leukemia relapse. 
These 22 non-relapse deaths were caused by infection (N= 
10), GVHD (N=4), hepatic venoocclusive disease (N=4), blee-
ding (N=2), thrombotic thrombocytopenic purpura (N=1), 
and suicide (N=1). The 5-year probabilities of OS and EFS 
were 20.6% and 14.0%, respectively (Fig. 1), and the 5-year 
CIR and NRM were 51.3% and 34.7%, respectively (Fig. 2).
2. Prognostic factor analysis
After univariate analyses, TBI (no vs. yes; OS at 5-year, 
25.0% vs. 7.7%; P=0.015), GVHD prophylaxis (methotrexate- 
containing vs. no methotrexate; 29.9 vs. 6.2%; P=0.054), 
HLA mismatch (no vs. yes; 22.2% vs. 11.1%; P=0.067), and 
donor-recipient sex pair (female to male vs. other; 0% vs. 
27.8%; P=0.079) were entered into a Cox proportional haz-
ards regression model for OS; duration of first CR (＜300 
days vs. ≥300 days; EFS at 5-year, 7.8% vs. 19.9%; P= 
0.085), TBI (no vs. yes; 17.8% vs. 0%; P=0.086), and GVHD Korean J Hematol 2010;45:95-101.
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Table 2. Multivariate analysis of prognostic factors for survival probabilities and cumulative incidences.
Variable Hazard ratio 95% Confidence interval P
Overall survival
Total body irradiation no vs. yes 2.300 1.154-4.586 0.018
a)
Event-free survival
GVHD prophylaxis MTX containing vs. no MTX 0.605 0.348-1.054 0.076
a)
Cumulative incidence of relapse
Cytogenetic finding at diagnosis t(9;22) or complex vs. others 2.787 1.442-5.388 0.002
b)
Disease status at HCT CR2 vs. not in remission 2.360 1.240-4.491 0.009
b)
Non-relapse mortality
GVHD prophylaxis MTX containing vs. no MTX 2.279 1.007-5.155 0.048
b)
Abbreviations: 
a)Cox proportional hazards regression model; 
b)Gray’s method.
MTX, methotrexate; HCT, hematopoietic cell transplantation; CR2, second complete remission; GVHD, graft-versus-host disease. 
Fig. 3. Cumulative incidence of relapse relative to salvage chemo-
therapy aimed at reinduction of complete remission (CR) before 
hematopoietic cell transplantation: second CR vs. untreated relapse vs.
refractory relapse.
prophylaxis (methotrexate-containing vs. no methotrexate; 
18.3% vs. 5.7%; P=0.073) were entered into a Cox propor-
tional hazards regression model for EFS; duration of first 
CR (＜300 days vs. ≥300 days; CIR at 5-year, 67.9% vs. 
35.5%; P=0.011), disease status at HCT (second remission 
vs. not in remission; 42.3% vs. 62.1%; P=0.040), and cytoge-
netic findings at diagnosis (t(9;22) or complex vs. others; 
81.8% vs. 44.5%; P=0.018) were entered into a multivariate 
model by Gray’s method for CIR; TBI (no vs. yes; NRM 
at 5-year, 29.8% vs. 53.9%; P=0.055) and GVHD prophylaxis 
(methotrexate-containing vs. no methotrexate; 26.0% vs. 
52.3%;  P=0.049) were entered into a multivariate model 
by Gray’s method for NRM. Acute or chronic GVHD did 
not have a significant influence on post-transplant outcomes 
in the univariate analyses. Table 2 shows the results of multi-
variate analyses of prognostic factors. TBI was an indepen-
dent prognostic factor for OS (hazard ratio [HR], 2.300; 95% 
confidence interval [CI], 1.154-4.586; P=0.018). GVHD pro-
phylaxis was a marginally significant prognostic factor for 
EFS (HR, 0.605; 95% CI, 0.348-1.054; P=0.076) and an in-
dependent prognostic factor for NRM (HR, 2.279; 95% CI, 
1.007-5.155;  P=0.048). Cytogenetic findings at diagnosis 
(HR, 2.787; 95% CI, 1.442-5.388; P=0.002) and disease status 
at transplantation (HR, 2.360; 95% CI, 1.240-4.491; P=0.009) 
were independent prognostic factors for CIR.
3. Role of salvage chemotherapy aimed at reinduction of CR 
before HCT
 P a t i e n t s  i n  t h e  s e c o n d  C R  b e f o r e  H C T  s h o w e d  a  s i g -
nificantly lower relapse rate than those who did not show 
remission before HCT. However, the latter group was divided 
into patients in the untreated relapse and refractory relapse 
groups, depending on whether they received salvage chemo-
therapy aimed at reinduction of CR before HCT. The 5-year 
CIR rate in the untreated relapse group (57.1%) was higher 
than that of the second remission group (42.3%), but it was 
lower than that for the refractory relapse group (66.7%) 
(Fig. 3). The median age of patients in second remission 
group was lower (31.0 vs. 40.5 vs. 43.0 years) and the median 
duration of the first CR was longer (367 vs. 168 vs. 131 
days) than that of patients in the untreated relapse or re-
fractory relapse groups. Among patients who underwent allo-
geneic HCT in relapse, those with ≤30% BM blasts had 
a lower 3-year CIR than those in florid relapse (BM blasts 
＞30%) (57.7% vs. 70.6%; Fig. 4). Table 3 shows 5-year 
estimates of OS, EFS, CIR, and NRM in patients in untreated 
first relapse, refractory relapse, and second CR groups.
DISCUSSION
Although many patients with acute leukemia do not un-
dergo allogeneic HCT during their first CR, it may be the 
only option for cure after relapse, and allogeneic HCT is 
performed depending on the disease characteristics and the 
discretion of the patients of their physicians. Because a small 
but significant proportion of patients with refractory acute 
leukemia can be cured by allogeneic HCT [23-27], a clinically Korean J Hematol 2010;45:95-101.
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Table 3. Clinical outcomes after allogeneic hematopoietic cell transplantation according to disease status.
5-year estimates Untreated relapse (N=14) Refractory relapse (N=15) Second CR (N=36)
Overall survival 16.1% 10.0% 26.3%
Event-free survival 14.3% 6.7% 17.3%
Cumulative incidence of relapse 57.1% 66.7% 42.3%
Non-relapse mortality 28.6% 26.7% 40.4%
Abbreviation: CR: complete remission.
Fig. 4. Cumulative incidence of relapse relative to bone marrow blast 
percentage before hematopoietic cell transplantation.
important issue in relapsed patients is not whether to perform 
allogeneic HCT but when this treatment should be per-
formed. Although allogeneic HCT in untreated first relapse 
has proven to be feasible, with a 23-29% 5-year DFS rate, 
a 44-57% 5-year relapse rate, and a 44-47% 5-year NRM 
rate [8, 10], only a few studies have addressed the issue 
regarding the optimal time for allogeneic HCT in acute leuke-
mia patients who relapse after non-transplantation treatment 
and who had a suitable hematopoietic cell donor, and differ-
ent results have been reported in these studies [12, 13, 15]. 
According to the Société Fançaise de Greffe de Möelle 
(SFGM) registry data on allogeneic HCT for advanced AML, 
the survival of patients receiving HCT in untreated relapse 
or refractory relapse was significantly lower than that of 
patients undergoing HCT in second or third CR (untreated 
relapse vs. refractory relapse vs. CR; OS, 14% vs. 11% vs. 
35%; DSF, 13% vs. 11% vs. 32%) [15]. However, others 
have reported that clinical outcomes in AML patients receiv-
ing allogeneic HCT during untreated first relapse were similar 
to or better than those for patients receiving allogeneic HCT 
in second or subsequent CR (untreated relapse vs. CR; OS, 
29% vs. 22%; relapse incidence 23% vs. 47%) [12]. In a 
study of pediatric patients with advanced AML, allogeneic 
HCT during second CR resulted in significantly better out-
comes than in patients with refractory disease, but the out-
comes did not differ significantly between patients in second 
CR and those in untreated first relapse (untreated relapse 
vs. refractory relapse vs. CR; DFS, 36% vs. 9% vs. 58%; 
relapse incidence, 36% vs. 74% vs. 42%) [13]. While the 
SFGM registry data suggested the importance of CR re-
induction before HCT in patients with relapsed acute leuke-
mia, two other studies found that attainment of second CR 
before HCT did not significantly improve clinical outcomes. 
Similarly, our results, showing that clinical outcomes of pa-
tients in untreated first relapse were between those of pa-
tients in refractory relapse and patients in second CR, suggest 
that salvage chemotherapy aimed at reinduction of CR is 
not beneficial in patients with relapsed acute leukemia who 
have suitable HCT donors. Reinduction chemotherapy may 
serve to select chemosensitive patients with better prognosis 
rather than improving clinical outcomes. Furthermore, re-
induction chemotherapy can result in mortality or serious 
morbidity before HCT. All of the above cited studies, includ-
ing ours, however, were retrospective in design, emphasizing 
the necessity for randomized prospective studies to de-
termine the optimal time for allogeneic HCT in relapsed 
acute leukemia patients. Moreover, our findings, that patients 
in early relapse (BM blasts ≤30%) had lower CIR rates 
than those in florid relapse (BM blasts ＞30%), were similar 
one study [12] but different from another [8].
The duration of the first CR is an important prognostic 
factor in relapsed acute leukemia patients [28]. We analyzed 
the effects of the duration of the first CR on post-transplant 
outcomes, and univariate analysis indicated that it was a 
significant risk factor for CIR, although the significance was 
not confirmed by multivariate analysis. Cytogenetic results 
at diagnosis have been shown to predict the outcomes of 
pre- and post-remission therapy for acute leukemia patients 
[29-31], as well as being associated with outcomes after allo-
geneic HCT in adults with AML in the first CR [32-34] 
or primary refractory AML [24] and in pediatric patients 
with advanced AML [13]. Multivariate analysis showed that 
the presence of unfavorable cytogenetic abnormalities (Phi-
ladelphia chromosome or complex karyotype) was associated 
with high CIR after HCT, indicating that unfavorable cytoge-
netics is a risk factor favoring allogeneic HCT for adult pa-
tients with advanced acute leukemia and suggesting that 
allogeneic HCT should be performed prior to relapse. Leuke-
mia relapse is a common cause of treatment failure after 
allogeneic HCT for advanced acute leukemia. One approach Korean J Hematol 2010;45:95-101.
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to reduce the risk of relapse is intensification of the prepara-
tive regimen. This approach showed promising results in 
some studies [8, 35], probably due to an increase in drug 
toxicities [14, 36]. In our study, the use of TBI-containing 
preparative regimens resulted in lower OS, mainly due to 
an increase in NRM. Although the results cannot be general-
ized to other populations because of the limitations of a 
retrospective study, this finding suggests that a more refined 
approach, rather than merely intensifying the preparative 
regimen, can reduce the risk of relapse without increasing 
NRM. Our study showed that patients receiving methotrex-
ate-containing regimens (usually cyclosporine or tacrolimus 
plus methotrexate) showed a significantly lower NRM and 
a tendency toward higher EFS than patients not receiving 
methotrexate (i.e., cyclosporine or tacrolimus alone) (Table 
3). Our results were similar to those of other studies [11, 
27], suggesting that optimal GVHD prophylaxis is essential 
even in patients with advanced acute leukemia. Furthermore, 
we failed to show antileukemic effects of GVHD (acute or 
chronic)(data not shown). However, some studies showed 
the importance of graft-versus-leukemia effects in advanced 
acute leukemia [10, 15, 36] and efforts are being focused 
on post-HCT immune modulation to increase graft-ver-
sus-leukemia effects without worsening GVHD. 
Our study has several limitations, primarily due to its 
retrospective design. The study population included both 
AML and ALL, and the heterogeneity may mislead the con-
clusion because graft-versus-leukemia effects are different 
between AML and ALL. We included, however, both disease 
entities because the treatment strategy and issue of salvage 
chemotherapy in relapsed patients before HCT are similar. 
We could not perform subgroup analyses due to limited 
number of patients. The transplantation procedures were 
variable in their conditioning regimens, GVHD prophylaxis, 
T-cell depletion of hematopoietic cells before infusion, and 
source of hematopoietic cells. Moreover, the 3 participating 
institutes differed in their treatment policy after first relapse. 
A prospective randomized trial is required to determine the 
optimal time for allogeneic HCT in relapsed acute leukemia 
patients. In addition, the role of novel therapeutic agents 
such as hypomethylating agents, tipifarnib, or clofarabine 
before HCT in relapsed acute leukemia should be investigated 
in future trials.
In summary, our results do not support the role of salvage 
chemotherapy aimed at reinduction of remission before allo-
geneic HCT in patients with acute leukemia after first relapse 
and suggest that at least the patients with early relapse do 
not appear to benefit from salvage chemotherapy before 
HCT.
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